Claims for Patent: 6,258,529

Summary for Patent: 6,258,529

Title:	PCR amplification of rearranged genomic variable regions of immunoglobulin genes
Abstract:	The invention features methods for isolating immunoglobulin variable region genes, and the use of these genes in the production of chimeric and isotype switched antibodies. The invention also features substantially pure DNA encoding a variable region of the antibody produced by hybridoma cell line HNK-20, and chimeric antibodies containing this variable region.
Inventor(s):	Berdoz; Jose (La Tour-de-Peilz, CH), Kraehenbuhl; Jean-Pierre (Rivaz, CH)
Assignee:	OraVax, Inc. (Cambridge, MA)
Application Number:	08/348,548
Patent Claims:	1. Substantially pure DNA comprising the sequence of SEQ ID NO:3, or degenerate variants thereof, and encoding the amino acid sequence of SEQ ID NO:4. 2. Substantially pure DNA comprising the sequence of SEQ ID NO:5, or degenerate variants thereof, and encoding the amino acid sequence of SEQ ID NO:6. 3. Substantially pure DNA comprising the sequence of SEQ ID NO:7, or degenerate variants thereof, and encoding the amino acid sequence of SEQ ID NO:8. 4. A method of isolating a nucleic acid comprising a variable region of an immunoglobulin gene from an organism, said method comprising the steps of: a. providing genomic DNA from said organism, wherein said genomic DNA comprises said variable region; b. providing a first set of primers, each of which contains the sequence of a polymorphic variant of a segment of the 5' untranslated region of an immunoglobulin gene from said organism; c. providing a second set of primers, each of which contains the sequence of a polymorphic variant of a segment of the intron 3' to the rearranged J region of an immunoglobulin gene from said organism; d. carrying out a polymerase chain reaction with said genomic DNA and said first and said second sets of primers; e. identifying a set of primers from said polymerase chain reaction that comprise sequences of said nucleic acid; and f. amplifying said nucleic acid with said identified set of primers. 5. The method of claim 4, wherein said immunoglobulin gene is from hybridoma cell line HNK-20.

Details for Patent 6,258,529

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26